Dry eye disease is not the same for everyone and our approach to treating it is changing.
In 2017, the Tear Film & Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) II report gave eye-care professionals a step-by-step approach to managing dry eye. In 2025, TFOS DEWS III updated that approach based on years of additional research, new diagnostic tools, and new treatment options.
So, what does this mean for patients with dry eyes?
It means treatment is becoming more personalized, more targeted, and more focused on identifying what is actually driving your symptoms.
What Was the DEWS II Approach?
The DEWS II report, published in 2017, introduced a staged, step-by-step approach to dry eye treatment.
It emphasized understanding whether a patient primarily had:
- Aqueous-deficient dry eye — not producing enough of the watery part of the tear film
- Evaporative dry eye — tears evaporating too quickly, often associated with meibomian gland dysfunction
Treatment would then progress through different levels depending on the patient’s response and disease severity.
This approach was an important step forward but our understanding of dry eye has continued to evolve.
What Is Different About DEWS III?
The 2025 DEWS III report moves away from thinking about dry eye as simply one category or another.
Instead, clinicians are encouraged to look more closely at the specific factors or “drivers” causing dry eye in each individual patient.
DEWS III organizes these drivers into three major areas:
1. Tear film deficiencies
Is there a problem with the lipid, aqueous, or mucin components of the tear film?
2. Eyelid anomalies
Are blinking, eyelid closure, blepharitis, or meibomian glands contributing to the problem?
3. Ocular surface abnormalities
Are inflammation, corneal or conjunctival changes, anatomical issues, or nerve-related problems contributing to symptoms?
A patient can have problems in more than one area at the same time.
Why Does This Matter?
Because two people with dry eyes may actually have very different problems.
One patient may have inadequate tear production.
Another may have blocked meibomian glands.
Someone else may have eyelid inflammation, incomplete blinking, ocular surface damage, or a combination of several factors.
DEWS III encourages clinicians to identify these underlying drivers rather than assuming that every patient should move through the same treatment steps.
Does This Mean Evaporative and Aqueous-Deficient Dry Eye No Longer Matter?
No.
These terms are still useful for understanding what is happening with the tear film. But DEWS III recognizes that many patients have overlapping causes, rather than fitting neatly into one category.
For example, a patient may have both reduced tear production and meibomian gland dysfunction.
The goal is to identify all of the important contributors and address them appropriately.
How Is Dry Eye Treatment Changing?
The treatment options themselves haven’t completely changed overnight. Many therapies used today were already part of dry eye care under DEWS II.
What has changed is how we think about choosing those treatments.
DEWS III emphasizes identifying the specific drivers of dry eye and matching treatment to what is actually contributing to each patient’s symptoms. Dr. Pradhan has always been focused on identifying each patient’s individual root cause when personalizing treatment plans.
Depending on what is found, treatment may include:
- Tear supplementation and stabilization
- Nutritional support
- Tear conservation
- Tear stimulation
- Anti-inflammatory treatments
- Meibomian gland treatments
- Lid hygiene and treatment of eyelid disease
- Ocular surface therapies
- In-office technologies
- Advanced or surgical treatments for appropriate patients
The goal is not simply to move from one treatment step to the next. Instead, clinicians are encouraged to identify the specific problems affecting the tear film, eyelids, and ocular surface and address those problems directly.
That is one of the most important differences between DEWS II and DEWS III.
What Does This Mean for Your Dry Eye Treatment?
It means there may no longer be a “one treatment fits all” approach and Dr. Pradhan has never treated dry eye this way. In her book, Goodbye, Dry Eye or her online course, you can discover more about her thought process behind figuring out what is the main cause of your dry eye disease.
The goal is to ask:
What is causing your dry eye?
- Is it your tear film?
- Your eyelids?
- Your meibomian glands?
- Your ocular surface?
- Inflammation?
- Blinking or incomplete eyelid closure?
- Or several of these working together?
Once the contributing factors are identified, treatment can be selected to address those specific problems.
How Will Dry Eye Treatment Evolve in the Future?
DEWS III is not the end of the story.
The report includes treatments and approaches where evidence is already established, while also identifying areas where more research is needed. As new studies, diagnostic tools, and therapies become available, treatment recommendations will continue to evolve.
This means the future of dry eye care will likely become increasingly personalized and mechanism-based with treatment chosen according to what is actually happening on and around each patient’s eye.
Intense Pulsed Light (IPL) Therapy
Long used in dermatology, IPL has revolutionized eye care since 2012 by targeting the root causes of ocular surface inflammation. Dr. Pradhan has been a pioneer of IPL therapy for dry eye disease in Virginia, performing treatments in her practice since December 2017!
IPL uses targeted light to reduce ocular surface inflammation, address abnormal blood vessels, and improve meibomian gland function by helping restore healthy oil flow.
OptiPlus Radiofrequency (RF) Treatment
OptiPlus uses controlled RF heat to soften clogged meibomian gland oils while improving circulation and stimulating collagen to support healthier eyelid function and tear stability.
OptiLift Dynamic Muscle Stimulation
The Optilift stimulates the orbicularis muscle for 7 minutes on each side to help strengthen the eyelid muscles, regulates your blink to help complete eyelid closure and help the meibomian glands express healthy meibum better.
What Does This Mean for You?
If you have been treating dry eyes but are still experiencing burning, irritation, fluctuating vision, redness, light sensitivity, or discomfort, it may be worth taking another look at what is driving your symptoms.
Dry eye disease is complex and your treatment should be individualized to you.
Ready to find out if IPL, OptiPlus, OptiLift or a combined treatment is the key to lasting dry eye relief? Call Eye Doctor MD, PC at (804) 270-3333 to schedule your dry eye evaluation with Dr. Pradhan!
Our goal is to understand why your eyes are uncomfortable and develop a personalized approach to help you achieve clearer, more comfortable vision.
Your dry eye deserves more than a one-size-fits-all solution. It deserves a closer look.
For more information on caring for your vision and whole-body health, subscribe to our YouTube channel.
Source:
- DEWS III report in review of ophthalmology https://www.reviewofophthalmology.com/article/treating-ded-patients-after-the-dews-iii-report

Dr. Shilpi Pradhan is a board-certified ophthalmologist, cornea specialist, and founder of Eye Doctor MD PC. Beyond providing advanced clinical treatments for dry eye disease, she guides patients in adopting targeted lifestyle changes to improve both their eye health and overall whole-body wellness. As one of the first Virginia ophthalmologists board-certified in Lifestyle Medicine (2020) and a member of the American College of Lifestyle Medicine (ACLM), Dr. Pradhan combines modern ocular care with evidence-based nutrition and habit changes to support long-term Vision Healthspan.

